Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

NanoVibronix, Inc. NAOV NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score
42/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

NanoVibronix, Inc. (NAOV) is a Medical - Devices company in the Healthcare sector, currently trading at $1.90. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Financials: revenue is $3M, +53.3%/yr average growth. Net income is $4M (loss), growing at +31.3%/yr. Net profit margin is -144.8% (negative). Gross margin is 59% (+13.6 pp trend).

Balance sheet: total debt is $116,000 against $627,000 equity (Debt-to-Equity (D/E) ratio 0.19, conservative). Current ratio is 1.22 (adequate). Debt-to-assets is 3.2%. Total assets: $4M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 0/100 (Fail), Health 50/100 (Partial), Moat 50/100 (Partial), Future ?/100 (Fail), Income 10/100 (Fail).

NAOV SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NAOV

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
100/100
NAOV: +53.3%/yr revenue is, +31.3%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet NAOV: Debt-to-Equity (D/E) ratio 0.19 (conservative), Current ratio is 1.22 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
NAOV: Gross margin is 59% (+13.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
NAOV: Net profit margin is -144.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.05-162.5
Volume98.18K
Avg Volume (30D)86.24K
Market Cap$1.51M
Beta (1Y)2.06
Share Statistics
EPS (TTM)-13.73
Shares Outstanding$2.7M
IPO Date2015-05-28
Employees31
CEODoron Robert Besser
Financial Highlights & Ratios
Revenue (TTM)$2.56M
Gross Profit$1.51M
EBITDA$-3.58M
Net Income$-3.71M
Operating Income$-3.58M
Total Cash$752K
Total Debt$116K
Net Debt$-636K
Total Assets$3.63M
Price / Earnings (P/E)-0.1
Price / Sales (P/S)0.59
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS63008J8844

Price Chart

Track all markets on TradingView
NAOV
NanoVibronix, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Devices
1.05 52WK RANGE 162.50

People Also View

RPID
RPID
Rapid Micro Biosystems, Inc.
$2.35
+7.31%
 VVOS
VVOS
Vivos Therapeutics, Inc.
$1.47
+8.89%
 SINT
SINT
Sintx Technologies, Inc.
$2.74
-2.14%
 BMRA
BMRA
Biomerica, Inc.
$2.11
+0.48%
 HSCS
HSCS
Heart Test Laboratories, Inc.
$1.98
+0.51%
 RMED
RMED
Ra Medical Systems, Inc.
$0.59
+10.00%
 BBLG
BBLG
Bone Biologics Corporation
$1.31
+3.97%
 RSLS
RSLS
ReShape Lifesciences Inc.
$3.92
+22.50%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message